Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a blank check company that completed its initial public offering in August 2020, filing its final prospectus on Form 424B4 with the SEC under accession number 0001213900-20-020382. The SPAC targeted the healthcare and biomedical technology sector, reflecting the heightened investor interest in life sciences vehicles during the 2020 SPAC surge. The company subsequently pursued a business combination with Orchestra BioMed, Inc., a cardiovascular-focused medical device and therapeutic development firm, transitioning the combined entity to an operating public company. For complete filing history, deal terms, sponsor details, and post-merger performance data on OBIO, sign up for full access at SpacDesk.